
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJerome Barley, Commercial Director, Avion MedicalRyan Klein, Vice President, Business Development, US and APAC, ResolianDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Can we finally get ahead of drug shortages?

Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November

Beyond the needle: The future of intratumoral therapy

Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.